Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 147 results for metastatic breast cancer

  1. Microwave ablation for primary or metastatic cancer in the lung (HTG609)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

    HealthTech guidance
    Published
    2 February 2022
    View recommendations

    Sections for HTG609

  2. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  3. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)

    Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.

    Technology appraisal guidance
    Published
    11 February 2026
    View recommendations

    Sections for TA1130

  4. Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG302

  5. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  7. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

    Medtech innovation briefing
    Published
    20 September 2017

  8. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.

    NICE guideline
    Last updated
    8 March 2024

    Sections for NG122

  9. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

    Technology appraisal guidance
    Published
    27 May 2020
    View recommendations

    Sections for TA630

  10. Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

    in combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012

    Research recommendation
    Published
    9 June 2015

  11. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011

    Research recommendation
    Published
    9 June 2015

  12. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  13. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  14. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG162

  15. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (HTG171)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

    HealthTech guidance
    Published
    23 July 2008
    View recommendations

    Sections for HTG171